Lombard Medical Files for Proposed IPO

March 11, 2014—Lombard Medical Technologies PLC (Oxfordshire, UK) announced that Lombard Medical, Inc. has filed a registration statement on Form F-1 with the US Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its ordinary shares.

Lombard focuses on medical devices for endovascular repair (EVAR) of abdominal aortic aneurysms (AAAs). The company’s lead product is the Aorfix endovascular stent graft, which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy that is often present in advanced AAA disease. The company is headquartered in Oxfordshire, England and has United States operations in Irvine, California.

According to the company, Lombard Medical intends to use proceeds from the proposed offering to expand its direct sales force in the United States and to develop new products to treat complex vascular disease, including a stent graft to treat aneurysms in the thoracic aorta. The remaining proceeds will be used for working capital and general corporate purposes.

Lombard Medical has reserved the ticker “EVAR” for its listing on the NASDAQ Global Market, and it will delist its ordinary shares from AIM, a market of the London Stock Exchange. The company will complete a change of domicile, with Lombard Medical, Inc., a Cayman Islands corporation, becoming the holding company for the group. The number of shares to be offered and the price range for the offering have not yet been determined.